No acquisitions were announced at J.P. Morgan this week but Abivax SA could soon find itself the subject of some serious takeover speculation following the French biotech's upbeat presentation at the high-profile healthcare conference centred around its Phase III-ready candidate, ABX464, for chronic inflammatory diseases.
The presentation came hours after EU regulators, just like the US Food and Drug Administration a month earlier, supported the...








